Lori E. Chapin’s Post

Legal Counsel, Corporate and Enabling Functions Genmab US, Inc.

2w Edited

Yes, Nunzia Delfino Kim Nevins Yesan "Analese" Rodgers, Isabel Brito-DeGrazio, I am home here at Genmab! Thank you for your kindness. What a lovely surprise. #grateful #colleagues #inhouse #biotech #inhouselife

2 Comments

Nunzia Delfino

Senior Manager @ Genmab | Proactive Talent Acquisition Strategies

Looking forward to working together and creating great things! :)

1 Reaction

Kim Nevins

Senior HR Leader @ Genmab | Building High-Performing Teams, HR Strategy and Solutions

So grateful for your expertise and partnership!

1 Reaction

See more comments

To view or add a comment, sign in

More Relevant Posts

VALIRX PLC

1,011 followers
11mo
Report this post
In case you missed it, last week we launched the latest edition of our LinkedIn newsletter, which we aim to release each month with comprehensive roundups of news and events concerning ValiRx. Head to our LinkedIn profile to catch up with the latest edition. We hope you enjoy the read and don't forget to subscribe. #Assays #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch
1 Comment
Like Comment
To view or add a comment, sign in
Syntara

3,103 followers
2mo
Report this post
"Syntara is not a one shot wonder. There's not just one technology going forward. We have in total four Phase Two studies that should deliver results by the middle of 2025. We have the funds to reach that point, which is really important for valuation." Watch the highlight below from CEO Gary Phillips' presentation at the recent ShareCafe Hidden Gems webinar. #Biotech #Syntara #SNT #HealthcareInnovation #ClinicalTrials #Syntara #Myelofibrosis
Like Comment
To view or add a comment, sign in
VALIRX PLC

1,011 followers
4mo
Report this post
In case you missed it, last week we released the latest in our company news roundups. In our latest edition, we share a comprehensive roundup of our news from January and February. We hope you enjoy the read: https://bit.ly/4a1DDSn #Assays #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch
Like Comment
To view or add a comment, sign in
VALIRX PLC

1,011 followers
10mo
Report this post
In case you missed it, we launched the latest edition of our news roundups, which we aim to release each month with comprehensive roundups of news and events concerning ValiRx. Head to our LinkedIn profile to catch up with the latest edition. We hope you enjoy the read and don't forget to subscribe. #Assays #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch
Like Comment
To view or add a comment, sign in
Inaphaea BioLabs

601 followers
11mo
Report this post
In case you missed it, last week we launched our new LinkedIn newsletter, which we aim to release each month with comprehensive roundups of news and events concerning Inaphaea BioLabs. Head to our LinkedIn profile to catch up with the first edition. We hope you enjoy the read and don't forget to subscribe. #Assays #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch
Like Comment
To view or add a comment, sign in
San Francisco Biotech Networks

4,962 followers
6mo
Report this post
SFBN Feed: JPM Day 2 has arrived. Here are the can’t-miss moments of the event so far https://lnkd.in/dwesiSXZ In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The Readout. To stay on top of the latest scoops and live reporting from the San… Click here to view original [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

JPM Day 2 has arrived. Here are the can’t-miss moments of the event so far

https://sfbn.org
Like Comment
To view or add a comment, sign in
Cheryl Allan

Associate Director - Branch Office Mgr at Oppenheimer & Co. Inc.
10mo
Report this post
In the latest Bio Banter episode, Michael Margolis, R.Ph., and Daniel Parisotto, Ph.D., discuss the H1 2023 activity of private biotech markets. Do they see continued strength or decline? On the one hand, deal-making activities declined from the zeal of the pandemic highs, but things still look good compared to pre-pandemic metrics. Curious for more? Tune in today. https://bit.ly/46k4zdZ #Therapeutics #Biotech #Oppenheimer #LetsTalkFuture
Like Comment
To view or add a comment, sign in
Cia Frey CRPC®

Associate Director - Investments
10mo
Report this post
In the latest Bio Banter episode, Michael Margolis, R.Ph., and Daniel Parisotto, Ph.D., discuss the H1 2023 activity of private biotech markets. Do they see continued strength or decline? On the one hand, deal-making activities declined from the zeal of the pandemic highs, but things still look good compared to pre-pandemic metrics. Curious for more? Tune in today. https://bit.ly/3Po0VJr #Therapeutics #Biotech #Oppenheimer #LetsTalkFuture
Like Comment
To view or add a comment, sign in
Trent Alton Birdsong, CPWA®, CIMA®, CFP®

Financial Advisor | Executive Director - Investments Oppenheimer & Co.
10mo
Report this post
In the latest Bio Banter episode, Michael Margolis, R.Ph., and Daniel Parisotto, Ph.D., discuss the H1 2023 activity of private biotech markets. Do they see continued strength or decline? On the one hand, deal-making activities declined from the zeal of the pandemic highs, but things still look good compared to pre-pandemic metrics. Curious for more? Tune in today. https://bit.ly/3PMS7Oz #Therapeutics #Biotech #Oppenheimer #LetsTalkFuture
Like Comment
To view or add a comment, sign in
Paul Damiba

Senior Director - Investments at Oppenheimer & Co. Inc.
10mo
Report this post
In the latest Bio Banter episode, Michael Margolis, R.Ph., and Daniel Parisotto, Ph.D., discuss the H1 2023 activity of private biotech markets. Do they see continued strength or decline? On the one hand, deal-making activities declined from the zeal of the pandemic highs, but things still look good compared to pre-pandemic metrics. Curious for more? Tune in today. https://bit.ly/452lhh7 #Therapeutics #Biotech #Oppenheimer #LetsTalkFuture
Like Comment
To view or add a comment, sign in

903 followers

496 Posts

View Profile Follow

Lori E. Chapin’s Post

More Relevant Posts

Explore topics